Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Nuvation Bio Inc. (NUVB)

1.83   -0.01 (-0.54%) 11-25 13:00
Open: 1.86 Pre. Close: 1.84
High: 1.905 Low: 1.83
Volume: 152,844 Market Cap: 398(M)

Technical analysis

as of: 2022-11-25 1:59:11 PM
Overall:       
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 2.51     One year: 2.79
Support: Support1: 1.76    Support2: 1.47
Resistance: Resistance1: 2.15    Resistance2: 2.39
Pivot: 1.93
Moving Average: MA(5): 1.83     MA(20): 2
MA(100): 2.54     MA(250): 4.29
MACD: MACD(12,26): -0.2     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 11.7     %D(3): 9.6
RSI: RSI(14): 33.5
52-week: High: 10.44  Low: 1.76
Average Vol(K): 3-Month: 633 (K)  10-Days: 487 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ NUVB ] has closed above bottom band by 20.6%. Bollinger Bands are 54.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.86 - 1.88 1.88 - 1.89
Low: 1.74 - 1.76 1.76 - 1.77
Close: 1.82 - 1.84 1.84 - 1.86

Company Description

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an adenosine receptor inhibitor; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as PARP inhibitor to address ER+ breast and ovarian cancer. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.

Headline News

Wed, 23 Nov 2022
Tracking Seth Klarman's Baupost Group Holdings - Q3 2022 Update - Seeking Alpha

Tue, 22 Nov 2022
Finance Stocks Lead Highs Tuesday; Markets Rise - InvestorsObserver

Fri, 18 Nov 2022
Stocks Creep Higher Friday as Oil Futures Flip into Contango - InvestorsObserver

Fri, 18 Nov 2022
Is Nuvation Bio Inc (NUVB) a Stock to Watch After Losing -8.00% This Week? - InvestorsObserver

Fri, 11 Nov 2022
Nuvation Bio Inc. (NUVB) Stock Price Today, Quote & News - Seeking Alpha

Wed, 09 Nov 2022
We Think Nuvation Bio (NYSE:NUVB) Can Afford To Drive Business Growth - Simply Wall St

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NYSE
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 218 (M)
Shares Float 118 (M)
% Held by Insiders 26.9 (%)
% Held by Institutions 71.5 (%)
Shares Short 5,030 (K)
Shares Short P.Month 7,820 (K)

Stock Financials

EPS -0.45
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 3.52
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -9.4
Return on Equity (ttm) -14
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.53
Qtrly Earnings Growth 0
Operating Cash Flow -88 (M)
Levered Free Cash Flow -52 (M)

Stock Valuations

PE Ratio -4.09
PEG Ratio 0
Price to Book value 0.51
Price to Sales 0
Price to Cash Flow -4.51

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.